Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06160921

Prognostic Model of Hypertension

The aim of this study was to establish a registration and monitoring system for hypertension in Xinjiang from 2020 to 2030 to obtain real information about patient basic information, patient characteristics, diagnostic test patterns, treatment options, and hospitalization outcomes (including mortality). Treatment complications, hospitalization costs, and end-of-life events (death, major adverse cardiac events, mild adverse cardiovascular events) in patients with hypertension in Xinjiang; and scientific prevention strategies aimed at effectively preventing the onset of hypertension; Guidelines in clinical practice recommend, analyze and develop effective treatment strategies to optimize management and outcomes for patients with hypertension; and create cost-effective assessment systems.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Hypertension Cardiovascular Diseases Vascular Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

The First Affiliated Hospital of Xinjiang Medicial University

Ürümqi, Xinjiang, 830000, China

Location status: Recruiting

Location contact

Xiang xie, PHD

CONTACT

[email protected]

15099169036

About this study

The aim of the study is to establish a platform for monitoring, clinical research and translational medicine in Xinjiang, which aims to provide a basis for future quality improvement and research, and to promote efforts to improve the prognosis of patients with hypertension, and to translate research into improved care for patients, thereby reducing Morbidity and mortality associated with hypertension.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • A patient diagnosed with primary hypertension who was admitted to the First Affiliated Hospital of Xinjiang Medical University

Exclusion criteria

  • Patients with secondary hypertension, patients with liver and kidney dysfunction,
  • patients with mental disorders, and patients who are unwilling to participate in this trial

Treatment and study plan

Standard therapy

Other

Individualized blood pressure reduction program

Primary outcomes

  1. Resistant hypertension

    Time frame: 10 years of follow-up Resistant hypertension occurred during this period

  2. Death (all-cause mortality, mortality from hypertension complications)

    Time frame: 10 years of follow-up deaths occurred during this period

Secondary outcomes

  1. Major adverse cardiovascular events

    Time frame: 10 years of follow-up deaths occurred during this period

Study contacts

Contact information is provided by the study sponsor or research team.

Xiang Xie, Phd

CONTACT

[email protected]

15099169036

Sponsors and collaborators

Lead sponsor

Xinjiang Medical University

Other

Registry information

Acronym: PHOP-HT

Important dates

Study start
2020
Primary completion
2030
Study completion
2030
First posted
Dec 7, 2023
Registry last updated
Mar 28, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.